Gyre Therapeutics

Yahoo Finance • last month

Undiscovered Gems in the US Market to Explore This December 2025

As the U.S. stock market continues to reach new heights, with the S&P 500 setting all-time records and major indices logging consecutive gains, investors are keenly observing the dynamics that drive these trends. In this buoyant environmen... Full story

Yahoo Finance • 3 months ago

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Ninteda... Full story

Yahoo Finance • 3 months ago

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, to... Full story

Yahoo Finance • 3 months ago

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic di... Full story

Yahoo Finance • 5 months ago

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic d... Full story

Yahoo Finance • 5 months ago

Jefferies initiates coverage on Crescent Biopharma stock with Buy rating

Investing.com - Jefferies initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and set a price target of $26.00. The stock, currently trading at $15.06, has shown strong momentum with a 9.21% return over the past we... Full story

Yahoo Finance • 5 months ago

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic di... Full story

Yahoo Finance • 6 months ago

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying tra... Full story

Yahoo Finance • 8 months ago

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic di... Full story

Yahoo Finance • 8 months ago

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic dis... Full story

Yahoo Finance • 8 months ago

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten... Full story

Yahoo Finance • 8 months ago

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering... Full story

Yahoo Finance • 8 months ago

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontin... Full story

Yahoo Finance • 10 months ago

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thromboc... Full story